Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting
December 11, 2023 01:45 ET
|
Ryvu Therapeutics
Clinical activity observed in 50% of evaluable patients with relapsed/refractory acute myeloid leukemia (r/r AML) or high-risk myelodysplastic syndromes (HR-MDS) treated with RVU120 monotherapy,...
Ryvu Therapeutics Presents Data on RVU120 at the San Antonio Breast Cancer Symposium 2023
December 07, 2023 08:30 ET
|
Ryvu Therapeutics
Translational data demonstrate synergistic activity of RVU120 and MEK inhibitors in hormone receptor-negative breast cancer KRAKOW, Poland, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics...
Ryvu Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 29, 2023 11:30 ET
|
Ryvu Therapeutics
The total operating revenues amounted to $11.9M and increased by 42% compared to Q3 2022.Updated data from Phase Ib study of RVU120 in AML/HR-MDS to be presented at the upcoming American Society of...
Molecure Announces Third Quarter 2023 Financial Results and Pipeline Highlights
October 31, 2023 04:00 ET
|
Molecure
U.S. Food and Drug Administration (FDA) approval to conduct a Phase II clinical trial for novel chitinase inhibitor OATD-01 in pulmonary sarcoidosis with first patient expected to be dosed in fourth...
Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120
October 23, 2023 02:50 ET
|
Ryvu Therapeutics
KRAKOW, Poland, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...
Ryvu Therapeutics to Present Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 04, 2023 12:30 ET
|
Ryvu Therapeutics
Poster presentations highlight preclinical data from Ryvu’s PRMT5 program in MTAP-Deficient cancers and its synthetic lethality platform in colorectal cancer modelsVirtual webinar on PRMT5 data and...
Molecure Announces First Half 2023 Results – Significant Financial and Operating Momentum
September 29, 2023 06:00 ET
|
Molecure
Molecure strategy update for 2023-2025 based on the development of a diversified portfolio of innovative research projects with the potential for breakthrough therapies for incurable diseasesCompleted...
Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update
September 13, 2023 03:00 ET
|
Ryvu Therapeutics
The total operating revenues amounted to $7.9M and increased by 131% compared to H1 2022.Updated clinical and preclinical data on RVU120 were presented at the European Hematology Associated (EHA)...
The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch
July 24, 2023 09:00 ET
|
Molecure
Press release The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch Molecure can proceed with clinical...
Molecure completes successful Secondary Public Offering (SPO) of approximately PLN 50 million (USD 12 million) with proceeds to be used to fund and build a first in class, sustainable pipeline of breakthrough therapies
July 21, 2023 03:00 ET
|
Molecure
Press release Molecure completes successful Secondary Public Offering (SPO) of approximately PLN 50 million (USD 12 million) with proceeds to be used to fund and build a first in class, sustainable...